| | Business Summary | | SangStat
Medical
Corporation
is
a
global
biotechnology
company
building
on
its
foundation
in
transplantation
to
discover,
develop
and
market
therapeutic
products
in
the
transplantation,
immunology
and
hematology/oncology
areas.
The
Company
sells
Thymoglobulin
(sold
under
the
name
Thymoglobuline
outside
the
United
States);
Gengraf
cyclosporine
capsule
(co-promoted
with
Abbott
Laboratories
in
the
United
States);
SangCya
Oral
Solution
-
cyclosporine
(outside
the
United
States);
Lymphoglobuline
(outside
the
United
States),
and
Celsior.
Its
principal
products
under
development
include
a
generic
cyclosporine
capsule,
ABX-CBL
(anti-CD147
antibody
in
co-development
with
Abgenix,
Inc.)
and
RDP58.
The
Company
previously
engaged
in
transplantation
services
through
The
Transplant
Pharmacy
(TTP).
SangStat
is
in
advanced
negotiations
with
a
bidder
and
expects
to
complete
the
sale
of
TTP
by
April
30,
2001. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | SANG
is
a
global
biotechnology
company
engaged
in
research
in
transplantation
to
discover,
develop
and
market
high
value
therapeutic
products
in
the
transplantation,
immunology
and
hematology/oncology
areas.
For
the
six
months
ended
6/30/01,
revenues
rose
52%
to
$42.1
million.
Net
loss
from
continuing
operations
fell
69%
to
$8.3
million.
Revenues
reflect
sales
of
Gengraf
and
higher
sales
of
Thymoglobulin.
Lower
loss
reflects
the
absence
of
a
$11.6
million
product
recall
charge. | | More
from
Market Guide: Significant
Developments |
| | Officers | | | FY1999 Pay | |
| Jean-Jacques Bienaime, 46
Chairman,
Pres, CEO, Chief Operating Officer | $355K | Stephen Dance, 49
Sr.
VP-Fin. | -- | Christophe Bianchi, M.D., 38
Sr.
VP, Global Marketing and Bus. Devel. and Pres of IMTIX-SangStat | -- | Steve Aselage, 48
Sr.
VP, North American Sales | -- | Roland Buelow, Ph.D., 41
Sr.
VP of Discovery Research | -- | | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/s/sang.gif)